



Astec LifeSciences Ltd.

Date: 23rd April, 2025

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on Wednesday, 23rd April, 2025, has approved the Audited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31st March, 2025.

We enclose a copy of the Press Release and the same is being placed on the website of the Company. Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As Above



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, 23rd April, 2025: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the fourth Quarter & Year ended March 31, 2025.

FINANCIAL OVERVIEW

Q4 FY25 Financial Summary

- The Company reported consolidated total income of Rs. 120.3 crore in Q4FY25 as compared to Rs. 155.8 crore in Q4FY24. Sequentially, the consolidated total income in Q4FY 25 was higher by 25.6% over Q3 FY25.
- The Company reported consolidated EBITDA of Rs. 6.3 crore in Q4FY25 as compared to Rs. 14.8 crore in the same period last year. EBITDA for Q4 FY25 showed a sequential improvement over Q3 FY 25.

FY 24-25 Financial Summary

- The Company reported consolidated total income of Rs. 386.9 crore in FY24-25 as compared to Rs. 463.8 crore in FY23-24
- The Company reported consolidated EBITDA loss of Rs. 60.6 crore in FY24-25 as compared to loss of Rs. 0.3 crore in the same period last year

HIGHLIGHTS OF CONSOLIDATED FINANCIAL PERFORMANCE (Q4FY25 and FY24-25)

(in Rs. crore)

Particulars	Q4FY25	Q3FY25	% Change	FY24-25	FY23-24	% Change
Total Income	120.3	95.8	25.5%	386.9	463.8	(17)%
Earnings before depreciation, interest and taxes (EBITDA)	6.3	(3.8)	NM	(60.6)	(0.3)	NM
Profit Before Tax (PBT)	(15.7)	(25.1)	NM	(141.0)	(61.7)	NM
Net Profit after Tax (PAT)	(16.1)	(40.4)	NM	(134.7)	(46.9)	NM

NM: Not Measurable

CHAIRMAN'S COMMENTS

Commenting on the performance, Mr. N. B. Godrej, Chairman, Astec LifeSciences Limited, said:

In Q4 FY25 Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs. 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to increase in volumes and prices in Enterprise business coupled with improved product mix in the CDMO business.

We expect uptick in the demand for Enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.

Revenue from Operations (in Rs. crore)	Q4FY25	Q3FY25	% Change	FY24-25	FY23-24	% Change
Category Breakdown						
Enterprise	50.5	34.1	48.1%	177.0	185.4	(4.5)%
Contract Manufacturing & New Products	69.0	59.8	15.4%	204.3	272.8	(25.1)%
Geography Breakdown						
Exports	96.0	69.6	37.9%	259.9	327.6	(20.7)%
Domestic	23.5	24.3	(3.3)%	121.4	130.6	(7.0)%

Q4FY25 highlights –

- In Q4 FY25, volumes in the Enterprise business registered a healthy growth of 2X as compared to Q4 FY24. However, profitability was adversely impacted on account of sharp decline in prices.
- While the demand for Enterprise products witnessed improvement, there was a significant drop in CDMO volumes when compared with Q4 FY24.

FY25 highlights –

- FY25 profitability has been adversely impacted on account of lower offtakes in the CDMO business coupled with sharp decline in the prices of its Enterprise products.
- The Company will continue to focus on building a strong pipeline of CDMO business and is taking all the efforts to achieve the same.

- ENDS –

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 17 countries including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

S. Varadaraj
Godrej Agrovet Limited
Email: s.varadaraj@godrejagrovet.com
Tel No.: +91 22 2519 4864

Mugdha Khare
Astec LifeSciences Limited
Email: mugdha.khare@godrejastec.com
Tel No.: +91 22 2519 5777

Gaurang Chotalia
Investor Relations
Email: gavlinvestors@godrejagrovet.com /
gaurang.chotalia@godrejagrovet.com
Tel No.: +91 22 2519 4646

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."